FDA approved Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
The Supreme Court last week upended one of the underpinnings of administrative law by weakening the authority of federal health agencies to rely on technical expertise as they regulate medical products, issue coverage decisions, and respond to public health crises.
